Silverarc Capital Management LLC Raises Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Silverarc Capital Management LLC raised its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 6.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 612,173 shares of the specialty pharmaceutical company's stock after purchasing an additional 37,615 shares during the quarter. Silverarc Capital Management LLC owned 1.24% of KalVista Pharmaceuticals worth $5,185,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. State Street Corp increased its position in shares of KalVista Pharmaceuticals by 68.1% during the 3rd quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company's stock worth $14,725,000 after purchasing an additional 515,179 shares during the last quarter. Barclays PLC increased its position in shares of KalVista Pharmaceuticals by 418.5% during the third quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company's stock valued at $778,000 after acquiring an additional 54,257 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of KalVista Pharmaceuticals by 3.1% in the 3rd quarter. Geode Capital Management LLC now owns 830,984 shares of the specialty pharmaceutical company's stock valued at $9,624,000 after acquiring an additional 24,713 shares during the period. JPMorgan Chase & Co. raised its stake in shares of KalVista Pharmaceuticals by 8.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company's stock valued at $262,000 after acquiring an additional 1,670 shares during the period. Finally, Hennion & Walsh Asset Management Inc. acquired a new position in shares of KalVista Pharmaceuticals in the 4th quarter worth approximately $634,000.

Insiders Place Their Bets

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 5,104 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total value of $50,121.28. Following the transaction, the chief executive officer now directly owns 278,855 shares in the company, valued at $2,738,356.10. This represents a 1.80 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Venrock Healthcare Capital Par acquired 25,000 shares of the business's stock in a transaction on Wednesday, April 9th. The shares were bought at an average cost of $9.42 per share, for a total transaction of $235,500.00. Following the acquisition, the insider now owns 5,303,985 shares of the company's stock, valued at $49,963,538.70. This represents a 0.47 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 261,055 shares of company stock worth $2,397,646 and sold 17,292 shares worth $184,625. 10.50% of the stock is currently owned by company insiders.

KalVista Pharmaceuticals Price Performance

Shares of KalVista Pharmaceuticals stock traded up $0.11 on Friday, reaching $12.99. 347,939 shares of the company were exchanged, compared to its average volume of 406,244. The stock's 50 day moving average price is $11.61 and its 200-day moving average price is $10.36. The company has a market cap of $645.81 million, a P/E ratio of -3.57 and a beta of 0.39. KalVista Pharmaceuticals, Inc. has a 1-year low of $7.30 and a 1-year high of $15.50.

Analyst Ratings Changes

A number of brokerages have issued reports on KALV. Needham & Company LLC reissued a "buy" rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 8th. HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Jones Trading restated a "buy" rating and set a $30.00 target price on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. JMP Securities began coverage on KalVista Pharmaceuticals in a research report on Friday, January 31st. They issued an "outperform" rating and a $19.00 target price for the company. Finally, TD Cowen initiated coverage on shares of KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating and a $30.00 price target on the stock. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $24.83.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).